Fuan Pharmaceutical Group Co (SHE:300194) — Market Cap & Net Worth
Market Cap & Net Worth: Fuan Pharmaceutical Group Co (300194)
Fuan Pharmaceutical Group Co (SHE:300194) has a market capitalization of $652.85 Million (CN¥4.46 Billion) as of August 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #10767 globally and #2898 in its home market, demonstrating a 4.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fuan Pharmaceutical Group Co's stock price CN¥3.75 by its total outstanding shares 1189712382 (1.19 Billion). See Fuan Pharmaceutical Group Co (300194) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Fuan Pharmaceutical Group Co Market Cap History: 2015 to 2026
Fuan Pharmaceutical Group Co's market capitalization history from 2015 to 2026. Data shows change from $1.02 Billion to $652.85 Million (-4.03% CAGR).
Fuan Pharmaceutical Group Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fuan Pharmaceutical Group Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.32x
Fuan Pharmaceutical Group Co's market cap is 0.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.77x
Fuan Pharmaceutical Group Co's market cap is 2.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.02 Billion | $708.10 Million | $64.90 Million | 1.44x | 15.69x |
| 2016 | $1.42 Billion | $1.30 Billion | $221.96 Million | 1.10x | 6.40x |
| 2017 | $939.80 Million | $2.09 Billion | $284.81 Million | 0.45x | 3.30x |
| 2018 | $534.24 Million | $2.67 Billion | -$359.98 Million | 0.20x | N/A |
| 2019 | $922.01 Million | $2.78 Billion | $292.83 Million | 0.33x | 3.15x |
| 2020 | $828.09 Million | $2.37 Billion | $209.37 Million | 0.35x | 3.96x |
| 2021 | $869.68 Million | $2.45 Billion | -$296.91 Million | 0.35x | N/A |
| 2022 | $611.50 Million | $2.42 Billion | $204.61 Million | 0.25x | 2.99x |
| 2023 | $753.00 Million | $2.65 Billion | $231.87 Million | 0.28x | 3.25x |
| 2024 | $776.45 Million | $2.39 Billion | $279.84 Million | 0.32x | 2.77x |
Competitor Companies of 300194 by Market Capitalization
Companies near Fuan Pharmaceutical Group Co in the global market cap rankings as of August 5, 2026.
Key companies related to Fuan Pharmaceutical Group Co by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Fuan Pharmaceutical Group Co Historical Marketcap From 2015 to 2026
Between 2015 and today, Fuan Pharmaceutical Group Co's market cap moved from $1.02 Billion to $ 652.85 Million, with a yearly change of -4.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥652.85 Million | -15.35% |
| 2025 | CN¥771.23 Million | -0.67% |
| 2024 | CN¥776.45 Million | +3.11% |
| 2023 | CN¥753.00 Million | +23.14% |
| 2022 | CN¥611.50 Million | -29.69% |
| 2021 | CN¥869.68 Million | +5.02% |
| 2020 | CN¥828.09 Million | -10.19% |
| 2019 | CN¥922.01 Million | +72.58% |
| 2018 | CN¥534.24 Million | -43.15% |
| 2017 | CN¥939.80 Million | -33.88% |
| 2016 | CN¥1.42 Billion | +39.59% |
| 2015 | CN¥1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Fuan Pharmaceutical Group Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $652.85 Million USD |
| MoneyControl | $652.85 Million USD |
| MarketWatch | $652.85 Million USD |
| marketcap.company | $652.85 Million USD |
| Reuters | $652.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, generic drugs, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and… Read more